Amyloid Beta (A4) Precursor Protein : A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma
© 2019 Li et al..
BACKGROUND AND AIM: Nasopharyngeal carcinoma (NPC) is one of the most common cancers in Southern China, Southeast Asia. Radiotherapy is the main treatment for NPC. Still, about 20% of patients with NPC have a recurrence. No effective serum biomarkers are available for recurrent nasopharyngeal carcinoma (rNPC) to date. This study aimed to explore whether amyloid beta (A4) precursor protein (APP) might serve as a valuable diagnostic and prognostic biomarker for patients with rNPC.
METHODS: In a previous study, a tandem mass tag-based proteomic test was performed, which screened 59 differentially expressed proteins (DEPs) between nonrecurrent nasopharyngeal carcinoma (nrNPC) and rNPC. In this study, a protein-protein interaction was conducted to screen the key proteins among the 59 DEPs. APP was validated and evaluated by enzyme-linked immunosorbent assay in 70 serum samples [recurrence (n = 35) and no-recurrence (n = 35)]. Also, the receiver operating characteristic (ROC) curve was plotted to evaluate the predictive value of APP.
RESULTS: The area under the ROC curve was 0.666 (95% CI: 0.514-0.818, P = 0.044). The best cutoff point of the relative expression levels for APP was 1.23 (concentration = 16.95 ng/mL), at which the sensitivity was 55.2% and the specificity was 90.9%.
CONCLUSION: The findings indicated that APP might be a valuable diagnostic and prognostic biomarker for patients with rNPC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Cancer management and research - 11(2019) vom: 28., Seite 10651-10656 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Xiao-Yu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloid beta precursor protein |
|---|
| Anmerkungen: |
Date Revised 12.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/CMAR.S218030 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305080326 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305080326 | ||
| 003 | DE-627 | ||
| 005 | 20231225120405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/CMAR.S218030 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1016.xml |
| 035 | |a (DE-627)NLM305080326 | ||
| 035 | |a (NLM)31908537 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Xiao-Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Amyloid Beta (A4) Precursor Protein |b A Potential Biomarker for Recurrent Nasopharyngeal Carcinoma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2019 Li et al. | ||
| 520 | |a BACKGROUND AND AIM: Nasopharyngeal carcinoma (NPC) is one of the most common cancers in Southern China, Southeast Asia. Radiotherapy is the main treatment for NPC. Still, about 20% of patients with NPC have a recurrence. No effective serum biomarkers are available for recurrent nasopharyngeal carcinoma (rNPC) to date. This study aimed to explore whether amyloid beta (A4) precursor protein (APP) might serve as a valuable diagnostic and prognostic biomarker for patients with rNPC | ||
| 520 | |a METHODS: In a previous study, a tandem mass tag-based proteomic test was performed, which screened 59 differentially expressed proteins (DEPs) between nonrecurrent nasopharyngeal carcinoma (nrNPC) and rNPC. In this study, a protein-protein interaction was conducted to screen the key proteins among the 59 DEPs. APP was validated and evaluated by enzyme-linked immunosorbent assay in 70 serum samples [recurrence (n = 35) and no-recurrence (n = 35)]. Also, the receiver operating characteristic (ROC) curve was plotted to evaluate the predictive value of APP | ||
| 520 | |a RESULTS: The area under the ROC curve was 0.666 (95% CI: 0.514-0.818, P = 0.044). The best cutoff point of the relative expression levels for APP was 1.23 (concentration = 16.95 ng/mL), at which the sensitivity was 55.2% and the specificity was 90.9% | ||
| 520 | |a CONCLUSION: The findings indicated that APP might be a valuable diagnostic and prognostic biomarker for patients with rNPC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a amyloid beta precursor protein | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a enzyme-linked immunosorbent assay | |
| 650 | 4 | |a protein–protein interaction | |
| 650 | 4 | |a recurrent nasopharyngeal carcinoma | |
| 700 | 1 | |a Meng, Hui-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Kai-Guo |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Xiao-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiao-Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Zhong-Guo |e verfasserin |4 aut | |
| 700 | 1 | |a Pan, Xin-Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Zeng, Fan-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Qu, Song |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer management and research |d 2009 |g 11(2019) vom: 28., Seite 10651-10656 |w (DE-627)NLM197692605 |x 1179-1322 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g day:28 |g pages:10651-10656 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/CMAR.S218030 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |b 28 |h 10651-10656 | ||